Biotechnology

Pharmaceuticals Clinical Trials Drug Development Clinical Research Pharmaceutical Industry Startups Research and Development Pharmaceutical Companies Acquisitions Biopharmaceuticals

Krystal Biotech Reports Strong Q1 on VYJUVEK, Readies Wider Launches

Strong profits paired with a large cash reserve signal capacity to fund expansion.

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

HHS Chief Distances From FDA Replimune Denial as Oncologists Dispute Review

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

Theriva’s VCN-01 Extends Survival in Phase 2b Pancreatic Cancer Trial, Paving Way to Phase 3

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

Definium Therapeutics Jumps to 52-Week High After Trump Order on Psychedelic Treatments

FDA Grants Orphan Drug Status to Immutep’s Efti for Soft Tissue Sarcoma

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

Hemmati Emerges as Front-Runner to Lead FDA’s Vaccine and Biologics Center

FDA Issues Second Rejection of Replimune’s RP1 Melanoma Therapy

Seer Confirms Unsolicited $2.25-Per-Share Takeover Bid From Radoff-JEC Group

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

AMA Assigns PLA CPT Code 0640U to Plus Therapeutics’ CNSide CSF Tumor Cell Test

Cyclerion to Merge With Korsana in Reverse Takeover Backed by $380 Million

Samsung Biologics Closes $280 Million Deal for GSK’s Maryland Plant

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Acoramidis Shows Durable Survival Benefit in ATTR-CM Through 54 Months

FDA Approves Higher‑Dose Spinraza Regimen for Spinal Muscular Atrophy